Covid vac­cine patent land­scape heats up as Pfiz­er's part­ner sues Ar­bu­tus and Genevant

The patent land­scape around the two top Covid-19 vac­cines is get­ting more com­plex and con­test­ed by the day.

Most re­cent­ly, Cana­di­an biotech Acuitas sued Ar­bu­tus and Genevant, two com­pa­nies that Acuitas be­lieves are mak­ing base­less claims about be­ing near the heart of Pfiz­er and BioN­Tech’s and Mod­er­na’s wild­ly suc­cess­ful Covid-19 vac­cines.

The suit comes as Acuitas’ LNP, or lipid nanopar­ti­cle, tech­nol­o­gy is used to de­liv­er Comir­naty via an es­tab­lished part­ner­ship. But the com­pa­ny says that “the de­fen­dants here, Ar­bu­tus and Genevant, had noth­ing to do with that suc­cess,” ac­cord­ing to a fil­ing Fri­day be­fore the US Dis­trict Court for the South­ern Dis­trict of New York.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER